Avalo Therapeutics (AVTX)Director bought ~$6.2K

~$6.2K

Approx. value · 500 sh @ $12.50

500

Holds after · shares reported

Traded

Nov 12, 2024

Filed

Nov 14, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 12, 2024 · this disclosureInsiderDirector purchased ~$6.2K of AVTX shares in the open market

What came next

1. Nov 13, 2024InsiderDirector purchased ~$6.5K of AVTX shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Avalo Therapeutics

For Avalo Therapeutics, OQRO holds 2 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its AVTX page.

Other recent filings by June Sherie Almenoff, Director

• SEC Form 4 at Tenax Therapeutics (TENX)Nov 20, 2025
• SEC Form 4 at Tenax Therapeutics (TENX)Nov 20, 2025
• SEC Form 4 at Avalo Therapeutics (AVTX)Nov 14, 2024

The full history of June Sherie Almenoff, Director is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Avalo Therapeutics

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRMay 15, 2026
• SEC Form 13F-HRFeb 17, 2026
• SEC Form 13F-HRNov 14, 2025
• SEC Form 13F-HRFeb 14, 2025

Everything OQRO holds on this company is on its AVTX page.